Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

Need for Flexible Adjustment of the Treatment Schedule for Aprepitant Administration against Erlotinib-Induced Refractory Pruritus and Skin Rush

Common dermatological side-effects associated with erlotinib, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), include pruritus and skin rash, which are mediated by substance P, leading to the occasional discontinuation of cancer treatment. Aprepitant is an antagonist of neur...

Full description

Bibliographic Details
Main Authors: Nobuhiko Seki, Ryosuke Ochiai, Terunobu Haruyama, Masashi Ishihara, Maika Natsume, Yoko Fukasawa, Takahiko Sakamoto, Shigeru Tanzawa, Ryo Usui, Takeshi Honda, Shuji Ota, Yasuko Ichikawa, Kiyotaka Watanabe
Format: Article
Language:English
Published: Karger Publishers 2019-01-01
Series:Case Reports in Oncology
Subjects:
Lung cancer
Erlotinib
Pruritus
Skin rush
Aprepitant
Online Access:https://www.karger.com/Article/FullText/493256

Internet

https://www.karger.com/Article/FullText/493256

Similar Items